Drug watch. Eye diseases.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2010 AND VI 45 AND IP 11
Results: 22
1
2
Meeting coverage. Rivaroxaban comparable to warfarin in stroke prevention.
- Published in:
- 2010
- Publication type:
- Journal Article
3
Meeting coverage. The non-specialty pharmaceutical pipeline: what's on the horizon?
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
Meeting coverage. Greater vigilance needed for unapproved agents; reduce demand for these drugs by reporting adverse events.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
5
Focus on 2010: a year of novel pharmacologic agents in review.
- Published in:
- 2010
- Publication type:
- Journal Article
6
Late-stage product development. Outcomes essential for adopting new leukemia therapies.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
7
Drug Watch. Eye diseases.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 364
- By:
- Publication type:
- Article
8
Policy Watch. Political changes in Washington create uncertainty for health reform, drug regulation, biomedical research.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 362
- By:
- Publication type:
- Article
9
Meeting Coverage. Rivaroxaban comparable to warfarin in stroke prevention.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 361
- Publication type:
- Article
10
Meeting Coverage. The non-specialty pharmaceutical pipeline: What's on the horizon?
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 360
- By:
- Publication type:
- Article
11
Meeting Coverage. Management with specialty Pharmaceuticals imminent for various conditions.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 359
- By:
- Publication type:
- Article
12
Meeting Coverage. Greater vigilance needed for unapproved agents; reduce demand for these drugs by reporting adverse events.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 359
- By:
- Publication type:
- Article
13
Medication Safety and Reliability. Ongoing FDA safety review: pioglitazone and potential increased risk of bladder cancer.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 358
- Publication type:
- Article
14
Focus on 2010: A year of novel pharmacologic agents in review.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 350
- Publication type:
- Article
15
Focus on... Azilsartan: A next-generation angiotensin II receptor blocker for the treatment of hypertension.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 342
- By:
- Publication type:
- Article
16
Aspirin reduces risk of colorectal cancer incidence, mortality.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 341
- Publication type:
- Article
17
Eplerenone reduces risk of death and hospitalization in patients with mildly symptomatic heart failure.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 340
- Publication type:
- Article
18
Study finds acetaminophen increases blood pressure in patients with coronary artery disease.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 340
- Publication type:
- Article
19
Late-stage Product Development. Outcomes essential for adopting new leukemia therapies.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 338
- By:
- Publication type:
- Article
20
FDA Drug Approvals. FDA actions in brief.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 336
- Publication type:
- Article
21
FDA Drug Approvals. New molecular entities.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 335
- Publication type:
- Article
22
FDA Drug Approvals. Pipeline preview.
- Published in:
- Formulary, 2010, v. 45, n. 11, p. 335
- Publication type:
- Article